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CHAPTER 1 1
As a consequence of the successful use of chemotherapy in the treatment of curable
neoplasms uch as test icu lar  cancer,  and the increasing appl icat ion of  (neo)adjuvant
chemotherapy for  var ious tumor types,  inc luding breast  cancer,  the number of  pa-
tients with a presumed normal l i fe expectancy after treatment is rising. Attention for
long-term side effects is therefore of growing importance. Evaluation of chronic car-
diovascular toxicity is of particular relevance since it may negatively influence the l ife
expectancy after chemotherapy. A number of cytostatic agents is well-known for their
toxic effects to the myocardium. Among these the most important are the anthracy-
c l ine ant ib iot ics,  such as doxorubic in and i ts  analogue epi rubic in,  and re lated com-
pounds such as mitoxantrone. By far the most important aspect of cardiotoxicity in-
duced by these agents is congestive heart failure, resulting from a cumulative dose-
re lated myocardia l  damage.  This damage occurs dur ing chemotherapy,  but  i t  may take
a long time before congestive heart failure develops. By means of non-invasive detec-
t ion techniques myocardia l  damage can be determined in an ear ly  s tage before con-
gest ive heart  fa i lure develops which may a l low ear ly  medical  in tervent ion wi th the
goal to prevent further progression. Until recently, other cytostatic agents such as
used in the treatment of patients with disseminated testicular cancer, were not known
to cause severe chronic cardiovascular toxicity. However, several reports have indi-
cated that a part of the patients who survives disseminated testicular cancer develops
an unfavorable cardiovascular risk-profi le and therefore may be prone to develop car-
d iovascular  d isease.
The a im of  th is  thesis  as formulated in  the in t roduct ion in  chapter  I  was to in-
vestigate the long-term effects of chemotherapy on the cardiovascular system, which
was main ly  s tudied in  test icu lar  cancer and breast  cancer pat ients,  t reated at  the Uni-
vers i ty  Hospi ta l  Croningen,  the Nether lands.
Chapter 2 is a review of the l iterature on cardiovascular toxicity related to the
use of cytostatic agents. Four patient groups with a good life expectancy after suc-
cessful chemotherapy were selected to review this issue: survivors of metastatic tes-
t icu lar  cancer and of  mal ignant  lymphomas t reated wi th curat ive chemotherapy,  and
.breast-  and colon cancer pat ients t reated wi th adjuvant  chemotherapy.  Besides d i rect
toxic effects of chemotherapy on the cardiovascular system also the indirect toxic ef-
fects such as chemotherapy re lated metabol ic  and hormonal  imbalances that  may ag-
gravate card iovascular  damage,  are d iscussed.  ln  surv ivors of  test icu lar  cancer the
most  ev ident  type of  long- term vascular  tox ic i ty  is  Raynaud's phenomenon.  Fur ther-
more, a part of this patient group develops an unfavorable cardiovascular risk-profi le
consist ing of  hypercholestero lemia and hypertension,  which to our  exper ience resul ts
in an increased r isk of  coronary ar tery d isease.  In  surv ivors of  mal ignant  lymphomas
and in patients treated with adjuvant chemotherapy for breast cancer the main type of
card iotox ic i ty  is  re lated to the use of  anthracycl ines,  which can resul t  in  congest ive
heart failure. This risk of cardiotoxicity may be aggravated by the use of thoracic irra-
d iat ion.  In  pat ients t reated wi th adjuvant  chemotherapy for  co lorecta l  cancer ,  only
acute card iotox ic i ty  (main ly  angina pector is)  is  repor ted re lated to the use of  5- f luo-
rouraci l  but  th is  does not  appear to be detr imenta l  in  the long- term.
In Chapter 3 a review of the l iterature is presented on the detection of anthra-
cyc l ine- induced card iotox ic i ty .  A l though endomyocardia l  b iopsy is  considered to be
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the most sensitive and specific test for this purpose, its use is l imited by its invasive-
ness.  In  dai ly  pract ice oncologists  usual ly  make use of  the non- invasive determinat ion
of the left ventricular ejection fraction to detect early cardiotoxicity, but this method
is not suitable to identif iT cardiotoxicity in an early stage. Based on increasing knowl-
edge into the pathophysiology of anthracycline-induce"d cardiotoxicitv and heart fail-
ure in  general ,  new methods inc luding the determinat ion of  d iasto l ic  funct ion pa-
rameters, heart rate variabil ity, and natriuretic peptides have been proposed to iden-
tify patients at risk for the development of congestive heart failure in an early stage.
However, most of these newer methods have not yet been adequately uu.lu.t"d"to
al low them to be recommended for  use in  rout ine c l ln icar  pract ice.
In Chapter 4 the results are presented of a follow-up study in testicular cancer
suryivors who had been treated 10 to 20 years previously with cisplatin based
chemotherapy. Since in previous studies it was shown that a number of testicular cancer
patients develops an unfavorable cardiovascular isk-profi le after chemotherapy,
consisting. of hypercholesterolemia, overweight and hypertension, we investigated
whether these cured patients in the long-term, are at an increased risk of develJping
cardiovascular morbidity and mortality. Therefore 87 patients treated with cispiati i
containing chemotherapy who were sti l l  in remission for at least 10 years and whose age
was 50 years or less at the time of the analysis, were evaluated for the o..urr"n." of
cardiovascular events. Major cardiac events were found in 5 of the g7 patients (age at
l ir.ne ol event 30-42 years; 9-16 years after chemotherapy): 2 patients had , *yo.Jrdirlinfarction and 3 patients angina pectoris with proven myoiardial ischemia. An increased
risk for Tj?nury artery disease, as compared io the general mare Dutch popuration wasfound. of these 
.8/ patients, 62 were additionally 
-evaluated 
for cardiac damage and
cardiovascular risk factors. Their cardiovascular risk profi le was compared to thal of 40
patients with comparable age and follow-up duration treated with orchidectomv onlv for
stage I testicular cancer- Echocardiography in the patients treated with chemotheiapy
showed a normal systolic left ventricular function in most patients, but the diastolic left
ventricular function was disturbed in 33%. Moreover, lgZ t 'taa hypercholesterolemia,
39% hypertension, 25% sti l l  experienced Raynaud's phenomenon, and 22 % had
microalbuminuria probably reflecting endotheiial dysfunction. Compared with stage I
patients, the chemotherapy treated patients had higher blood pressures, higher tital
serum cholesterol- and triglyceride levels and *"r" .or" insulin resistant. The
pathogenesis of the observed increased risk of coronary artery disease is unclear, but this
may be l inked with several factors, including metabolicand hormonal changes related to
gonadal toxicity, possibly resulting in the development of a syndrome X- l ike state. The
latter is suggested by the combination of overweight, microalbuminuria, hypertension,
insul in  res is tance and dysl ip idemia found in some of  these pat ients.  Fur thermore.  the
induction of chronic endothelial dysfunction may play a iole. Accurate follow-up,
focused on cardiovascular complications and aiming at intervention in these young
cancer-survivors, appears to be of great impodance in the near future.
Exposure to c isp lat in  combinat ion chemotherapy seems wi th the current  data an
important  contr ibut ing factor  in  the occurrence of  card iovascular  d isease in lons- term
survivors of metastatic testicular cancer. The interval between chemotEerapy
treatment  in  these pat ients and the development  of  card iovascular  d isease mav ta le
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more than 10 years.
For this reason we hypothesized in chapter 5 whether the observed increased
r isk of  card iovascular  d isease might  be re lated to pro longed retent ion of  c isp lat in  in
the body. Therefore we measured plasma platinum concentrations using a very
sensitive assay. In this assay high-pressure decomposition of samples was performed,
followed by an adsorptive voltammetric measurement. Plasma platinum
concentrations in the patients studied were compared with those of 20 control
patients who were cured from stage I testicular cancer by orchidectomy without
chemotherapy. In all 61 tested patients who were ' l 0-20 years after cisplatin
adminis t rat ion,  p lat inum was detectable wi th a mean concentrat ion of  64.9 pglg
plasma, whereas in  the contro l  group p lat inum concentrat ions were not  detectable.
The height of the platinum concentration was related to the cumulative dose
administered and inversely related to the renal function. These results suggest that
platinum is recirculating in the plasma between potential body stores such as the l iver,
bone,  and muscle.  These chronic low plasma concentrat ions of  p lat inum may p lay a
ro le in  the development  of  card iovascular  morbid i ty  af ter  chemotherapy.
In chapter 6 we describe the results of the investigations regarding the mag-
nesium status in long-term survivors of testicular cancer. Hypomagnesemia in general
has been associated wi th hypertension,  abnormal  ip id metabol ism, and accelerated
atheroscleros is ,  and the occurrence of  vascular  ischemic events.  Cisplat in  can cause
proximal- tubule damage that  resul ts  in  renal  magnesium wast ing.  The t ime dur ing
which th is  magnesium deplet ion pers is ts  af ter  t reatment  is  not  known. Since about  99
% of the total body magnesium is located intracellularly, determination of the red-
b lood cel l  magnesium concentrat ion might  be a bet ter  ind icator  of  the magnesium
status than the serum magnesium concentrat ion.  In  addi t ion,  a low int racel lu lar  mag-
nesium content  is  associated wi th hypertension and insul in-res is tance.  Both red-b lood
cel l  magnesium concentrat ion (assessed by an indi rect  method) and the serum mag-
nesium concentrat ion were measured in 50 surv ivors of  test icu lar  cancer who were 10
to 20 years after treatment. These data were compared with the magnesium status of
a contro l  group of  17 pat ients wi th test icu lar  cancer not  t reated wi th chemotherapy.
We found that  a l though the mean serum concentrat ion of  magnesium in both groups
did not differ, the red-blood cell magnesium content in the group of patients treated
wi th chemotherapy was s igni f icant ly  lower than in the contro l  group.  These data sug-
gest that up. to 20 years after cisplatin-containing chemotherapy survivors of testicular
cancer are st i l l  magnesium def ic ient ,  a l though the serum magnesium concentrat ion is
normal .  This  d is turbed magnesium equi l ibr ium might  p lay a ro le in  the development
of  unfavorable card iovascular  r isk-orof i le  observed in these oat ients.
In chapter  7 we descr ibe a (p i lo t )  s tudy per formed in breast  cancer pat ients,
who had been t reated wi th anthracycl ines and i r radiat ion,  in  order  to invest igate ar ly
s igns of  card iotox ic i ty  in  these pat ients.  These pat ients had a l l  par t ic ipated in  h igh-
dose chemotherapy schedules inc luding auto logous bone- or  s tem cel l  t ransplanta-
tion. We tested whether analysis of the heart rate variabil ity calculated from a 24-hr
Hol ter  regis t rat ion,  as measure for  the autonomic tone,  and assessment  of  the d ia-
stolic function by echocardiography could help to identify early signs of cardiotoxicity.
Therefore twenty females treated for breast cancer with high-dose anthracycline-
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based chemotherapy were evaluated. None of these patients had signs or symptoms
of heart disease and all had a normal systolic left ventricular function. One or more
echocardiographic diastolic parameters were abnormal in 50 % of the patients. HRV
frequency parameters were even abnormal in 85 % of the patients. Mean values of
both time domain and frequency domain parameters were decreased, in particular the
parasympathetic indexes compared to a control group consisting of healthy age-
matched females. lt was concluded that autonomic impairment occurs in a large pro-
portion of asymptomatic patients with normal systolic LV function after high-dose
anthracycline-based chemotherapy and seems to be an early sign of cardiotoxicity af-
ter treatment.
To explore these findings further in a more homogenous population we
evaluated in chapter 8 in a cross-sectional design the cardiac function by means of
various detection techniques in 56 breast cancer patients two or more years after
epirubicin-containing chemotherapy combined with locoregional irradiation. Patients
had been treated within a randomized phase ll l  study comparing 5 cycles of 5-
fluorouracil, epirubicin (90 mg/m'z), and cyclophosphamide (FEC) (n=30) with 4 cycles
of FEC followed by high-dose chemotherapy consisting of cyclophosphamide (6g/. '),
th iotepa and carboplat in  (n=26).  The main f ind ings of  th is  s tudy showed that  11% of
all patients had a decreased systolic function and 38% an impaired diastolic function.
HRV parameters reflecting vagal activity in the whole patient group were significantly
impaired compared to healthy age-matched controls. ln30% of the patients exertional
dyspnea was present. These patients were characterized by an impaired diastolic
function and a reduced HRV compared to patients without these symptoms. No
difference in cardiotoxicity was found between the treatment regimens. This study
showed that in a substantial number of breast cancer patients treated with a relatively
low cumulative dose of epirubicin signs of mild chronic cardiotoxicity are present two
or more (maximum 6.5) years after treatment.
Following this cross-sectional study, we describe in chapter 9 the results of a
prospective evaluation of the cardiac function of 40 breast cancer patients who were
treated in  the same phase l l l  t r ia l  as descr ibed in chapter8.  Of  them 21 pat ients were
treated with 5 cycles of FEC and 19 with 4 cycles of FEC followed by high-dose
chemotherapy consist ing of  cyc lophosphamide,  th iotepa and carboplat in .  The card iac
function of these patients was evaluated before chemotherapy, after completion of
chemotherapy but before radiotherapy, after radiotherapy and one year after
chemotherapy. During the studied period, none of the patients in this study
developed congestive heart failure. However, various indications of an impairment of
the cardiac function were observed including a decline in the mean left ventricular
e iect ion f ract ion (LVEF),  resul t ing in  an abnormal  LVEF in17% of  the pat ients.  Plasma
levels of natriuretic peptides increased gradually in the course of t ime and an increase
in the QTc time was observed. No persistent alterations were found in the diastolic
function and the HRV, although the HRV was temporarily reduced shortly after
chemotherapy in patients treated with the high-dose regimen. The observed changes
in cardiac function indicate mild cardiotoxicity one year after start of treatment which




In chapter 10 suggestions with respect to further research are described. lt is
important to outl ine the prevalence of cardiovascular toxicity due to cytostatic agents
and to investigate the pathogenesis. Thereafter attempts should be made to amelio-
rate or even prevent the cardiovascular side effects of cytostatic agents. The ultimate
goal  wi l l  be adding to a successfu l  t reatment  of  pat ients wi th cancer,  a maximizat ion
of  thei r  chances of  a long and heal thy l i fe  by designing st rategies for  pr imary and sec-
ondary prevention of long-term toxic effects of chemotherapy.
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